Sir, We enjoyed reading the article entitled 'Cell-free nucleic acids as noninvasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy' by Traver et al. (2014) . It is now widely accepted that massively parallel sequencing of maternal plasma DNA provides high sensitivity and specificity for non-invasive detection of fetal aneuploidy (Wang et al., 2014 (Wang et al., , 2015 . However, recent studies have raised concerns about high false-positive rates of such noninvasive prenatal testing (NIPT) assays reaching up to 7% for trisomy 21 (Wang et al., 2015) . One important consideration is the impact of the maternal genome as a possible cause of false-positive results, including gynecological conditions (Lau et al., 2013; Traver et al., 2014) . There is also another important factor to consider; the presence of constitutional maternal chromosomal mosaicism.
We analyzed a 28-year-old primigravida who was enrolled into our research study under an IRB-approved protocol due to abnormal fetal ultrasound showing cystic hydroma at 10 weeks of gestation. NIPT using plasma DNA sequencing, coupled with the 'Minimally Invasive Karyotyping' (MINK) analysis algorithm (Chu et al., 2009) was performed and returned a significant P-value consistent with a gain in copy number of chromosome 21, yet the fetal karyotype was normal as determined by chorionic villus sampling (CVS) followed by classical chromosome and FISH analyses. NIPT was initially interpreted as a false-positive finding. However, we suspected there might be a biological explanation and performed high-resolution copy number variation analyses of maternal genomic DNA, CVS derived DNA and maternal plasma DNA. By comparing the affected maternal plasma and maternal genomic DNA libraries, respectively, against normal plasma and normal genomic DNA libraries, we identified a gain of 26% in maternal plasma and a gain of 28% in maternal genomic DNA involving the 21q11.2-q22.12 chromosome region (chr21:14 350 000-32 650 000) (Fig. 1A and B) .
Similarly, microarray analysis on a pure maternal DNA sample revealed a gain in the chr21:14 420 615-32 635 501 (hg19) region, which is suggestive of a mosaicism for an extranumerary abnormal chromosome 21 (Fig. 1C) . FISH analysis on uncultured interphase cells from maternal peripheral blood ( Fig. 1D and E) showed 28% of cells with an additional chromosome 21.
Our data demonstrate that an apparent 'false-positive' NIPT result for trisomy 21 was due to maternal somatic mosaicism for an extranumerary chromosome 21. Recurrent trisomy 21 in offspring of young, apparently healthy parents has been explained in some families by maternal germline mosaicism, also reviewed by Taylor et al. (2014) . We would like to raise an important issue on interpretation of positive NIPT findings and clinical significance of chromosomal mosaicism. Sequencing of the maternal plasma may reveal a maternal genomic abnormality which may elevate the risk of future pregnancies with trisomy 21, trisomy for an abnormal chromosome or 21q deletion. Despite the lack of current apparent health consequences of mosaic trisomy 21 for the mother, she may have elevated risk for hematopoietic malignancy and/or dementia and late onset conditions. Gonadal and somatic mosaicism for point mutations is a well-documented cause for a number of genetic diseases; however low-level mosaicism for aneuploidy or structurally abnormal chromosomes is likely also a common phenomenon, yet underestimated. We propose that all positive NIPT results should be followed by diagnostic fetal testing, parental DNA analysis, and genetic counseling. Oligonucleotide probes represented by colored dots on a log 2 scale (Y-axis) and arranged on X-axis according to the Human Genome assembly (GRCh37/ hg19) position from the centromere (left) to the telomere (right) of chromosome 21. Black dots indicate normal copy number for DNA probes with mean log 2 of 0.0. Gain of copy number (blue dots) is detected for regions with a positive log 2 ratio (above 0), while red dots with a negative log 2 ratio (below 0) indicate loss of DNA copy number. Mean log 2 ratio of +0.58 is expected for an extra copy gain in 100% of the cells. Reply: Cell-free nucleic acids as non-invasive biomarkers of gynecological disorders, fetal aneuploidy and constitutional maternal chromosomal mosaicism Sir, We thank Drs Chu and Peters for their interest in our review on the use of circulating nucleic acids (microRNAs and cell-free DNA) as noninvasive biomarkers of gynecological and pregnancy-related disorders.
We agree with Drs Chu and Peters that non-invasive prenatal testing (NIPT) is not perfectly reliable. Indeed, a positive cell-free DNA testing result does not always imply the presence of fetal aneuploidy. As it was specified by Drs Chu and Peters in their Letters to the Editor, Wang et al., reported that NIPT can have very high false-positive rates, for instance up to 7% for trisomy 21 detection (Wang et al., 2014) . This finding illustrates the necessity to be careful in the case of positive results and to confirm them systematically before taking any decision concerning the pregnancy management. Moreover, it is also important to understand the possible causes of discordant results that decrease the positive predictive value of this test, in order to improve its clinical development and applications.
In our review we aimed mainly to highlight the emerging role of circulating nucleic acids as non-invasive tools for the detection of ovarian disorders and for the prediction of in vitro fertilization (IVF) outcome. Indeed, currently we quantify cell-free DNA (cfDNA) concentration and microRNA expression in biological fluids in order to develop new non-invasive diagnostic and/or prognostic tests in human reproductive medicine that could be used to improve IVF outcome. For instance, we have already shown that the analysis of cell-free DNA in follicular fluid samples might offer the possibility to develop a non-invasive test for the selection of the embryos with the highest implantation potential (Scalici et al., 2014 Diagnostic and management modalities in early tubal ectopic pregnancy with focus on safety Sir, The paper by Kirk et al. (2014) on diagnostic modalities for ectopic pregnancy (EP) and management of pregnancy of unknown location (PUL) is a very succinct and balanced review covering a wide range of important issues. The discussion about the role of ultrasound scanning combined with serial human chorionic gonadotrophin (bhCG) estimation in diagnosis of tubal EP is particularly useful. This letter further debates a few particular aspects. Kirk et al. (2014) state that in their specialist early pregnancy unit (EPU) up to 73.9% of EP were visualized on transvaginal ultrasound scan (TVUS). The most common finding (60%) was a 'nonhomogeneous mass' in the adnexa separate from the ovary (a blob sign). However, other pathologies (e.g. broad ligament fibroids, ovarian cysts, fimbrial cysts or even faecoliths) can be mistaken for a blob sign as indeed pointed out by Kirk et al. (2014) . For these reasons the 'American consensus statement on nomenclature of PUL' reserves the term 'definite EP' to those when an extra-uterine gestation sac containing a yolk sac or fetal pole is visualized (Barnhart et al., 2011) and 'blob sign' is called 'probable ectopic' pregnancy. Kirk et al. (2014) have pointed out how this distinction is crucial when treatment with methotrexate is considered. Hence it could be argued that it would be preferable to have one standard safe terminology (i.e. 'probable ectopic' for a blob sign), otherwise a potential risk of someone somewhere inadvertently administering methotrexate to an early viable intrauterine pregnancy is instigated.
Secondly, many EPUs in the UK do not perform TVUS before 6 weeks (when dates known) unless there is pain in addition to bleeding. This reasonable strategy seems useful in reducing the incidence of PULs. Moreover, the experience of many EPUs in district general hospitals is that a significant proportion of early unruptured ectopic pregnancies may not be visualized on TVUS and scans are generally not repeated before 7-10 days unless there is increased acute pain. Hence, many units depend on combination of TVUS and serial bhCG estimation to diagnose tubal ectopic pregnancy. Kirk et al. (2014) have very well highlighted the false positive and negative rates of such an approach. Every protocol/ guideline on methotrexate treatment for EP should mention at the outset that a possibility of intrauterine pregnancy must be ruled out. A suboptimal rise of bhCG of ,35% over 48 h may be one option (Kirk et al., 2014) . The other option could be to require suboptimal
